A traditional Chinese medicine composition for fatty liver and / or hyperuricemia

Abstract

This invention discloses a traditional Chinese medicine composition for fatty liver and / or hyperuricemia and its application. The composition comprises the following herbs in parts by weight: 10-30 parts raw Coix seed, 8-24 parts Polyporus umbellatus, 8-24 parts Poria cocos, 5-20 parts Atractylodes lancea, 5-20 parts Phellodendron chinense, 5-20 parts stir-fried Atractylodes macrocephala, 10-30 parts Alisma plantago-aquatica, 5-18 parts prepared Pinellia ternata, 5-20 parts Citrus reticulata peel, 5-18 parts Magnolia officinalis, 8-24 parts Bupleurum chinense, 5-20 parts Forsythia suspensa, 5-20 parts stir-fried Areca catechu, and 5-20 parts Citrus aurantium. This traditional Chinese medicine composition can be used to treat fatty liver and / or hyperuricemia, achieving the effect of "treating different diseases with the same method," providing a new treatment option for patients with single or dual lipid-protein metabolic disorders.

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to a traditional Chinese medicine composition for fatty liver and / or hyperuricemia. Background Technology

[0002] Fatty liver and hyperuricemia are two major metabolic diseases that seriously threaten human health. Their prevalence is on the rise and has become a global public health problem.

[0003] Fatty liver disease (now often referred to as metabolic-associated fatty liver disease, MASLD) has become the most common chronic liver disease worldwide. Epidemiological surveys show that the prevalence of MASLD in the general population worldwide is approximately 30%-32% (Hua Chen, et al. Metabolic and hepatic biomarkers associated with MASLD in the Chinese population[J]. Scientific Reports. 2025;15:31593. DOI: 10.1038 / s41598-025-17219-3). Fatty liver disease can not only progress to steatohepatitis, liver fibrosis, cirrhosis, and even hepatocellular carcinoma, but it is also closely related to the occurrence and development of extrahepatic complications such as cardiovascular disease and type II diabetes.

[0004] Under normal purine dietary conditions, a fasting blood uric acid level above 420 μmol / L (approximately 7.0 mg / dL) for men and above 360 ​​μmol / L (approximately 6.0 mg / dL) for women, measured on two separate days, is sufficient to diagnose hyperuricemia. Alternatively, regardless of gender, a blood uric acid level exceeding 420 μmol / L (7.0 mg / dL) is considered hyperuricemia. Hyperuricemia is considered the "fourth high" after hypertension, hyperglycemia, and hyperlipidemia. Although it exhibits significant regional and population differences globally, its overall global prevalence is 6%-8%, making it the second most common metabolic disease after type II diabetes. Hyperuricemia itself is usually asymptomatic, but its long-term presence can directly cause tissue and organ damage. It is not only the root cause of gout but also an independent risk factor for many other metabolic diseases, including obesity, diabetes, cardiovascular disease, hypertension, and chronic kidney disease.

[0005] There is a close pathophysiological link between fatty liver and hyperuricemia, and the two often co-occur and are mutually causal. Recent studies have found that lipid metabolism disorders can directly induce hyperuricemia. Hyemin Jeong et al. reported that in a survey of 15,935 participants in South Korea, the prevalence of metabolic syndrome among gout patients could be as high as 66.5% (Hyemin Jeong et al. Gout comorbidities: results from the Korean National Health and Nutrition Examination Survey[J]. Advances in Rheumatology. 2024;64:76;DOI:10.1186 / s42358-024-00413-8). This coexistence of "dual metabolic disorders" further amplifies the risks of cardiovascular disease progression, liver disease progression, and kidney damage in patients, significantly increasing the difficulty of clinical intervention. Currently, there are no small molecule drugs or biologics that simultaneously address both fatty liver and hyperuricemia. In clinical practice, patients with hyperuricemia and fatty liver often require combination therapy, which further increases the risk of drug interactions and the incidence of adverse reactions.

[0006] Traditional Chinese medicine theory holds that both fatty liver and hyperuricemia belong to the category of deficiency in the root and excess in the branch, with insufficient vital energy and excessive pathogenic factors. The pathogenesis is based on spleen deficiency or spleen-kidney deficiency, with damp-heat, phlegm, turbidity, and blood stasis as the branch. Treatment focuses on strengthening the spleen and soothing the liver, resolving phlegm and removing blood stasis, and clearing damp-heat, achieving the effect of "treating different diseases with the same method." For example, Chinese invention patent application CN113440584A (publication date September 28, 2021) discloses a traditional Chinese medicine composition for the treatment of non-alcoholic fatty liver disease, including 1-5 parts of Phellodendron bark, 1-5 parts of Atractylodes lancea, 1-5 parts of Coix seed, and 1-5 parts of Achyranthes bidentata. This composition can not only slow down weight gain and reduce the content of total triglycerides in the liver and total cholesterol in the serum, but also reduce the content of uric acid in the serum. Chinese invention patent application CN117244021A (published on December 19, 2023) discloses a traditional Chinese medicine combination extract for lowering blood sugar, blood lipids, blood pressure, and uric acid, and its preparation method. The raw materials of the traditional Chinese medicine combination extract are Dioscorea hypoglauca, winter melon peel, hawthorn, sheep hoof, Ophiopogon japonicus, Gastrodia elata, Dendrobium nobile, Ligustrum lucidum, Elsholtzia ciliata, Vitex trifolia, and mulberry leaves.

[0007] However, the incidence of fatty liver and hyperuricemia remains high, indicating that clinical needs are far from being met. Summary of the Invention

[0008] Based on the high consistency between fatty liver and hyperuricemia in the pathogenesis of traditional Chinese medicine, this application provides a traditional Chinese medicine composition that can be used to treat fatty liver and / or hyperuricemia, playing the role of "treating different diseases with the same method", and providing a new treatment option for patients with single or dual lipid-protein metabolic disorders.

[0009] The first objective of this application is to provide a traditional Chinese medicine composition for fatty liver and / or hyperuricemia, comprising the following traditional Chinese medicines in parts by weight:

[0010] Raw coix seed 10-30 parts by weight, Polyporus umbellatus 8-24 parts by weight, Poria cocos 8-24 parts by weight, Atractylodes lancea 5-20 parts by weight, Phellodendron chinense 5-20 parts by weight, stir-fried Atractylodes macrocephala 5-20 parts by weight, Alisma plantago-aquatica 10-30 parts by weight, Pinellia ternata 5-18 parts by weight, Citrus reticulata peel 5-20 parts by weight, Magnolia officinalis 5-18 parts by weight, Bupleurum chinense 8-24 parts by weight, Forsythia suspensa 5-20 parts by weight, Areca catechu 5-20 parts by weight, and Citrus aurantium 5-20 parts by weight.

[0011] Preferably, the traditional Chinese medicine composition for fatty liver and / or hyperuricemia consists of the following traditional Chinese medicines in parts by weight:

[0012] 10-20 parts by weight of raw coix seed, 10-20 parts by weight of polyporus umbellatus, 10-20 parts by weight of poria cocos, 5-15 parts by weight of atractylodes lancea, 5-15 parts by weight of phellodendron bark, 5-15 parts by weight of stir-fried atractylodes macrocephala, 10-20 parts by weight of alisma plantago-aquatica, 5-15 parts by weight of prepared pinellia ternata, 5-15 parts by weight of tangerine peel, 5-15 parts by weight of magnolia bark, 10-20 parts by weight of bupleurum chinense, 5-15 parts by weight of forsythia suspensa, 5-15 parts by weight of charred areca nut, and 5-15 parts by weight of euphorbia pekinensis.

[0013] More preferably, the traditional Chinese medicine composition for fatty liver and / or hyperuricemia is composed of the following traditional Chinese medicines in parts by weight:

[0014] 12-18 parts by weight of raw coix seed, 10-15 parts by weight of polyporus umbellatus, 10-15 parts by weight of poria cocos, 8-12 parts by weight of atractylodes lancea, 8-12 parts by weight of phellodendron chinense, 8-12 parts by weight of stir-fried atractylodes macrocephala, 12-18 parts by weight of alisma plantago-aquatica, 8-12 parts by weight of prepared pinellia ternata, 8-12 parts by weight of tangerine peel, 8-12 parts by weight of magnolia officinalis, 10-15 parts by weight of bupleurum chinense, 8-12 parts by weight of forsythia suspensa, 8-12 parts by weight of charred areca nut, and 8-12 parts by weight of euphorbia pekinensis.

[0015] Most preferably, the traditional Chinese medicine composition for fatty liver and / or hyperuricemia consists of the following traditional Chinese medicines in parts by weight:

[0016] 15 parts by weight of raw coix seed, 12 parts by weight of polyporus umbellatus, 12 parts by weight of poria cocos, 10 parts by weight of atractylodes lancea, 10 parts by weight of phellodendron bark, 10 parts by weight of stir-fried atractylodes macrocephala, 15 parts by weight of alisma plantago-aquatica, 9 parts by weight of prepared pinellia ternata, 10 parts by weight of tangerine peel, 9 parts by weight of magnolia bark, 12 parts by weight of bupleurum chinense, 10 parts by weight of forsythia suspensa, 10 parts by weight of charred areca nut, and 10 parts by weight of euphorbia pekinensis.

[0017] A second objective of this invention is to provide the application of the above-mentioned traditional Chinese medicine composition in the preparation of a medicament for treating fatty liver.

[0018] A third objective of this invention is to provide the application of the above-mentioned traditional Chinese medicine composition in the preparation of a medicament for treating hyperuricemia.

[0019] The fourth objective of this invention is to provide the application of the above-mentioned traditional Chinese medicine composition in the preparation of a medicament for treating fatty liver complicated with hyperuricemia.

[0020] In this article, "hyperuricemia" refers to a serum uric acid level ≥420 μmol / L (7.0 mg / dL), regardless of gender.

[0021] Patients with fatty liver and / or hyperuricemia may also present with hypertension, hyperlipidemia, dizziness, obesity, gout, and / or diarrhea.

[0022] Preferably, the above-mentioned drug is a clinically acceptable formulation.

[0023] More preferably, the preparation is an oral preparation, selected from decoctions, tablets, capsules, powders, pills or granules.

[0024] The drug also includes pharmaceutically acceptable excipients.

[0025] The pharmaceutically acceptable excipients include (1) solvents, such as distilled water, ethanol, etc.; (2) diluents, such as starch, powdered sugar, dextrin, lactose, pregelatinized starch, microcrystalline fiber, inorganic calcium salts (such as calcium sulfate, calcium hydrogen phosphate, pharmaceutical calcium carbonate, etc.), mannitol, vegetable oil, polyethylene glycol, etc.; (3) binders, such as distilled water, ethanol, starch paste, sodium carboxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose and ethyl cellulose, hydroxypropyl methyl cellulose, etc.; (4) disintegrants, such as dry starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, etc.; (5) lubricants, such as magnesium stearate, micronized silica gel, talc, hydrogenated vegetable oil, polyethylene glycol, magnesium lauryl sulfate, etc.

[0026] The present invention also provides a method for preparing the above-mentioned drug, comprising preparing each traditional Chinese medicine raw material according to the stated weight proportions, adding pharmaceutically acceptable excipients, and preparing a clinically acceptable formulation according to conventional methods in the art.

[0027] As a preferred embodiment, the present invention provides a method for preparing a decoction for fatty liver and / or hyperuricemia, using the traditional Chinese medicine composition described in the present invention as raw material, comprising the following steps:

[0028] I. Prepare each medicinal material according to its weight proportions;

[0029] II. Mix all the herbs and soak them in 10-15 times their weight of water for 30-60 minutes;

[0030] III. After soaking, bring to a boil over high heat, then reduce to low heat and simmer for 30-60 minutes; filter while hot; add 5-10 times the weight of water to the dregs, bring to a boil over high heat, then reduce to low heat and simmer for 30-40 minutes; filter while hot; combine the two filtrates, and concentrate to a suitable volume if necessary, to obtain the final product.

[0031] The traditional Chinese medicine composition described in this application comprises raw coix seed, polyporus umbellatus, and poria cocos as principal herbs; atractylodes lancea, stir-fried atractylodes macrocephala, alisma plantago-aquatica, and phellodendron chinense as assistant herbs; pinellia ternata, tangerine peel, bupleurum chinense, and forsythia suspensa as adjuvant herbs; areca catechu as adjuvant herb; and eucommia ulmoides as guiding herb. Each herb performs its specific function and works synergistically to jointly resolve phlegm and dampness, soothe the liver, and strengthen the spleen.

[0032] In this application, the "parts by weight" of medicinal materials refers to the relative proportion of each medicinal material used, rather than the actual mass. Depending on the actual situation, 1 part by weight can be any mass, such as 1g, 10g, 500g, 1kg, etc. Detailed Implementation

[0033] The present invention will be described below with reference to specific embodiments. Those skilled in the art will understand that these embodiments are for illustrative purposes only and do not limit the scope of the invention in any way.

[0034] Unless otherwise specified, the experimental methods used in the following examples are conventional methods. Unless otherwise specified, all medicinal materials and reagents used in the following examples are commercially available products.

[0035] Example 1: A traditional Chinese medicine composition and a decoction

[0036] The medicinal materials composition of the traditional Chinese medicine composition described in this embodiment are as follows:

[0037] 15g raw coix seed, 12g polyporus umbellatus, 12g poria cocos, 10g atractylodes lancea, 10g phellodendron chinense, 10g stir-fried atractylodes macrocephala, 15g alisma plantago-aquatica, 9g prepared pinellia ternata, 10g tangerine peel, 9g magnolia officinalis, 12g bupleurum chinense, 10g forsythia suspensa, 10g charred areca nut, 10g euphorbia pekinensis.

[0038] Using the above-mentioned Chinese herbal medicine composition as raw material, the decoction of this embodiment is obtained by decocting twice with water. The specific operation is as follows:

[0039] I. Prepare each medicinal material according to the indicated quality;

[0040] II. Mix all the herbs together and soak them in 10 times their weight of water for 30 minutes;

[0041] III. After soaking, bring to a boil over high heat, then reduce to low heat and simmer for 45 minutes; filter while hot; add 8 times the weight of water to the dregs, bring to a boil over high heat, then reduce to low heat and simmer for 35 minutes; filter while hot; combine the two filtrates, and concentrate to a suitable volume if necessary, to obtain the final product.

[0042] Dosage and administration: Divide the decoction into two portions, take one portion twice a day, one portion in the morning and one portion in the evening.

[0043] Example 2: A traditional Chinese medicine composition and a decoction

[0044] The medicinal materials composition of the traditional Chinese medicine composition described in this embodiment are as follows:

[0045] 10g raw coix seed, 8g polyporus, 8g poria, 5g atractylodes, 5g phellodendron, 5g stir-fried atractylodes macrocephala, 10g alisma, 5g prepared pinellia, 5g tangerine peel, 5g magnolia bark, 8g bupleurum, 5g forsythia, 5g charred areca nut, 5g euryale seed.

[0046] Using the above-mentioned Chinese herbal composition as raw material, a decoction was obtained by following the same procedure as in Example 1, with the dosage and usage being the same as in Example 1.

[0047] Example 3: A traditional Chinese medicine composition and a decoction

[0048] The medicinal materials composition of the traditional Chinese medicine composition described in this embodiment are as follows:

[0049] 12g raw coix seed, 10g polyporus umbellatus, 10g poria cocos, 8g atractylodes lancea, 8g phellodendron chinense, 8g stir-fried atractylodes macrocephala, 12g alisma plantago-aquatica, 158g prepared pinellia ternata, 8g tangerine peel, 8g magnolia officinalis, 10g bupleurum chinense, 8g forsythia suspensa, 12g charred areca nut, 8g euryale ferox.

[0050] Using the above-mentioned Chinese herbal composition as raw material, a decoction was obtained by following the same procedure as in Example 1, with the dosage and usage being the same as in Example 1.

[0051] Example 4: A traditional Chinese medicine composition and a decoction

[0052] The medicinal materials composition of the traditional Chinese medicine composition described in this embodiment are as follows:

[0053] 18g raw coix seed, 15g polyporus umbellatus, 15g poria cocos, 12g atractylodes lancea, 12g phellodendron chinense, 12g stir-fried atractylodes macrocephala, 18g alisma plantago-aquatica, 12g prepared pinellia ternata, 12g tangerine peel, 12g magnolia officinalis, 15g bupleurum chinense, 12g forsythia suspensa, 12g charred areca nut, 12g euryale ferox.

[0054] Using the above-mentioned Chinese herbal composition as raw material, a decoction was obtained by following the same procedure as in Example 1, with the dosage and usage being the same as in Example 1.

[0055] Example 5: A traditional Chinese medicine composition and a decoction

[0056] The medicinal materials composition of the traditional Chinese medicine composition described in this embodiment are as follows:

[0057] 20g raw coix seed, 20g polyporus umbellatus, 20g poria cocos, 15g atractylodes lancea, 15g phellodendron chinense, 15g stir-fried atractylodes macrocephala, 20g alisma plantago-aquatica, 15g prepared pinellia ternata, 15g tangerine peel, 15g magnolia officinalis, 20g bupleurum chinense, 15g forsythia suspensa, 15g charred areca nut, 15g euphorbia pekinensis.

[0058] Using the above-mentioned Chinese herbal composition as raw material, a decoction was obtained by following the same procedure as in Example 1, with the dosage and usage being the same as in Example 1.

[0059] Clinical Practice Examples: Typical medical cases of the traditional Chinese medicine composition of the present invention used in the clinical treatment of fatty liver and / or hyperuricemia.

[0060] The traditional Chinese medicine composition of this invention has achieved good clinical results in treating fatty liver and / or hyperuricemia. Generally, in severely ill patients, relevant blood biochemical indicators significantly improve and essentially return to normal after about three weeks of medication; simultaneously, systemic symptoms also show marked improvement. The following are only selected typical medical cases; other cases will not be elaborated upon here.

[0061] 1. Patient 1, Li XX, male, 43 years old, first visit on August 21, 2025.

[0062] The patient reported: moderate fatty liver, gout, toe joint pain, staying up late, high blood pressure, difficulty falling asleep, frequent dreams, and constipation; red tongue with a white, greasy coating, and a slippery pulse. Recent blood biochemistry test results: total cholesterol: 8.7 mmol / L, triglycerides: 4.2 mmol / L, high-density lipoprotein: 2.1 mmol / L, low-density lipoprotein: 3.6 mmol / L, uric acid: 420 μmol / L.

[0063] The decoction of Example 1 was taken once a day, twice a day, for 21 consecutive days; no other medications were taken during this period.

[0064] On September 11, 2025, the patient returned for a follow-up visit. The patient reported that the symptoms had improved, sleep and bowel movements were normal, blood pressure was 130 / 90, and toe pain had been relieved. The tongue coating was thin and white, and the pulse was slow. The blood biochemical indicators showed significant improvement: total cholesterol: 5.43 mmol / L, triglycerides: 1.71 mmol / L, high-density lipoprotein: 1.2 mmol / L, low-density lipoprotein: 2.3 mmol / L, and uric acid: 413.5 μmol / L.

[0065] 2. Patient 2, Ms. Xu, 51 years old, first visit on July 24, 2025. Patient's self-report: Abdominal ultrasound diagnosed mild to moderate fatty liver; elevated total cholesterol, elevated blood pressure, elevated uric acid; loose stools, occasional diarrhea, occasional sputum production, difficulty falling asleep, frequent awakenings, and poor sleep. Red tongue with greasy coating, slippery pulse. Recent blood biochemistry test results: Total cholesterol: 6.02 mmol / L, triglycerides: 3.79 mmol / L, high-density lipoprotein: 1.07 mmol / L, low-density lipoprotein: 3.9 mmol / L, uric acid: 433 μmol / L.

[0066] The decoction in Example 3 was taken once daily, twice a day, for 21 consecutive days without any other medications. The patient returned for a follow-up visit on August 14, 2025. The patient reported: abdominal ultrasound was normal, blood pressure was normal, bowel movements and sleep were normal. The tongue coating was thin and white, and the pulse was slow. Repeat blood biochemistry tests showed essentially normal levels: total cholesterol: 5.31 mmol / L, triglycerides: 1.82 mmol / L, high-density lipoprotein: 1.34 mmol / L, low-density lipoprotein: 3.1 mmol / L, uric acid: 403.08 μmol / L.

[0067] 3. Patient 3, Lou XX, male, 38 years old, first visit on June 5, 2025. Patient's self-reported symptoms: weight 200 catties; abdominal ultrasound diagnosed moderate fatty liver; high blood pressure; dark yellow urine; 3-4 loose, sticky bowel movements daily, difficulty defecating, prone to diarrhea; difficulty falling asleep, frequent dreams, poor sleep quality; excessive phlegm upon waking; bad breath; dry and bitter mouth; easily irritated. Obese physique, oily complexion, red tongue with greasy coating, slippery pulse. Recent blood biochemistry test results: total cholesterol: 9.3 mmol / L, triglycerides: 3.71 mmol / L, high-density lipoprotein: 0.9 mmol / L, low-density lipoprotein: 5.1 mmol / L, uric acid: 480 μmol / L.

[0068] The patient had consulted other doctors and taken 21 doses of herbal decoction, but there was no significant improvement. The prescription was as follows: 10g each of Atractylodes lancea and Atractylodes macrocephala, 10g each of Poria cocos and Poria cocos, 8g each of Citrus reticulata and Citrus reticulata peel, 15g of Pueraria lobata, 10g of Scutellaria baicalensis, 6g of Coptis chinensis, 1g of Evodia rutaecarpa, 15g of Paeonia lactiflora, 9g of Saposhnikovia divaricata, 15g each of the three roasted herbs (Horse, Hawthorn, and Fructus Hordei), 10g of Pogostemon cablin, and 6g of Aucklandia lappa.

[0069] The decoction from Example 5 was administered once daily, twice a day, for 21 consecutive days. The patient returned for a follow-up visit on June 26, 2025. The patient reported significant improvement in overall symptoms, formed stools, normal blood pressure, improved sleep quality, no phlegm or bad breath upon waking, and a weight loss of 8 catties; the tongue coating was thin and white, and the pulse was slow. Follow-up blood biochemical indicators were basically normal: total cholesterol: 5.73 mmol / L, triglycerides: 1.65 mmol / L, high-density lipoprotein: 1.55 mmol / L, low-density lipoprotein: 3.2 mmol / L, uric acid: 400.05 μmol / L.

[0070] In summary, this invention provides a traditional Chinese medicine composition with the effects of resolving phlegm and dampness, soothing the liver and strengthening the spleen, and has a definite curative effect on fatty liver and / or hyperuricemia.

Claims

1. A traditional Chinese medicine composition for fatty liver and / or hyperuricemia, comprising the following traditional Chinese medicines in parts by weight: Raw coix seed 10-30 parts by weight, Polyporus umbellatus 8-24 parts by weight, Poria cocos 8-24 parts by weight, Atractylodes lancea 5-20 parts by weight, Phellodendron chinense 5-20 parts by weight, stir-fried Atractylodes macrocephala 5-20 parts by weight, Alisma plantago-aquatica 10-30 parts by weight, Pinellia ternata 5-18 parts by weight, Citrus reticulata peel 5-20 parts by weight, Magnolia officinalis 5-18 parts by weight, Bupleurum chinense 8-24 parts by weight, Forsythia suspensa 5-20 parts by weight, Areca catechu 5-20 parts by weight, and Citrus aurantium 5-20 parts by weight.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, The traditional Chinese medicine composition comprises the following traditional Chinese medicines in parts by weight: 10-20 parts by weight of raw coix seed, 10-20 parts by weight of polyporus umbellatus, 10-20 parts by weight of poria cocos, 5-15 parts by weight of atractylodes lancea, 5-15 parts by weight of phellodendron bark, 5-15 parts by weight of stir-fried atractylodes macrocephala, 10-20 parts by weight of alisma plantago-aquatica, 5-15 parts by weight of prepared pinellia ternata, 5-15 parts by weight of tangerine peel, 5-15 parts by weight of magnolia bark, 10-20 parts by weight of bupleurum chinense, 5-15 parts by weight of forsythia suspensa, 5-15 parts by weight of charred areca nut, and 5-15 parts by weight of euphorbia pekinensis.

3. The traditional Chinese medicine composition according to claim 2, characterized in that, The traditional Chinese medicine composition comprises the following traditional Chinese medicines in parts by weight: 12-18 parts by weight of raw coix seed, 10-15 parts by weight of polyporus umbellatus, 10-15 parts by weight of poria cocos, 8-12 parts by weight of atractylodes lancea, 8-12 parts by weight of phellodendron chinense, 8-12 parts by weight of stir-fried atractylodes macrocephala, 12-18 parts by weight of alisma plantago-aquatica, 8-12 parts by weight of prepared pinellia ternata, 8-12 parts by weight of tangerine peel, 8-12 parts by weight of magnolia officinalis, 10-15 parts by weight of bupleurum chinense, 8-12 parts by weight of forsythia suspensa, 8-12 parts by weight of charred areca nut, and 8-12 parts by weight of euphorbia pekinensis.

4. The traditional Chinese medicine composition according to claim 3, characterized in that, The traditional Chinese medicine composition comprises the following traditional Chinese medicines in parts by weight: 15 parts by weight of raw coix seed, 12 parts by weight of polyporus umbellatus, 12 parts by weight of poria cocos, 10 parts by weight of atractylodes lancea, 10 parts by weight of phellodendron bark, 10 parts by weight of stir-fried atractylodes macrocephala, 15 parts by weight of alisma plantago-aquatica, 9 parts by weight of prepared pinellia ternata, 10 parts by weight of tangerine peel, 9 parts by weight of magnolia bark, 12 parts by weight of bupleurum chinense, 10 parts by weight of forsythia suspensa, 10 parts by weight of charred areca nut, and 10 parts by weight of euphorbia pekinensis.

5. The use of the traditional Chinese medicine composition according to any one of claims 1 to 4 in the preparation of a medicament for treating fatty liver.

6. The use of the traditional Chinese medicine composition according to any one of claims 1 to 4 in the preparation of a medicament for treating hyperuricemia.

7. The use of the traditional Chinese medicine composition according to any one of claims 1 to 4 in the preparation of a medicament for treating fatty liver complicated with hyperuricemia.

8. The application according to any one of claims 5 to 7, characterized in that, The drug is a clinically acceptable formulation; Preferably, the preparation is an oral preparation selected from decoctions, tablets, capsules, powders, pills, or granules.

9. A medicament for fatty liver and / or hyperuricemia, using the traditional Chinese medicine composition of any one of claims 1 to 4 as a raw material, and further comprising pharmaceutically acceptable excipients.

10. The method for preparing the drug according to claim 9, comprising preparing each of the traditional Chinese medicine raw materials according to the weight proportions of any one of claims 1 to 4, adding pharmaceutically acceptable excipients, and preparing a clinically acceptable formulation according to conventional methods in the art; Preferably, when the preparation is a decoction, the preparation method includes the following steps: I. Prepare the medicinal materials according to the weight proportions described in any one of claims 1 to 4; II. Mix all the herbs and soak them in 10-15 times their weight of water for 30-60 minutes; III. After soaking, bring to a boil over high heat, then reduce to low heat and simmer for 30-60 minutes; filter while hot; add 5-10 times the weight of water to the dregs, bring to a boil over high heat, then reduce to low heat and simmer for 30-40 minutes; filter while hot; combine the two filtrates, and concentrate to a suitable volume if necessary, to obtain the final product.